IMorningside Ventures namhlanje ibhengeze ukuphehlelelwa kwe-Adiso Therapeutics, inkampani yeklinikhi ye-biotechnology eqhubela phambili umbhobho wenoveli yonyango ejolise kwizifo ezosulelayo. I-Morningside iye yaxhasa ngemali izicwangciso zophuhliso lwe-Adiso ukuza kuthi ga ngoku, kunye nezicwangciso zokuxhasa ngakumbi ukukhula okukhawulezayo kwenkampani ukuya phambili.
I-Adiso iqhubela phambili umbhobho owenziweyo weeathom ezincinci kunye neendlela ezintsha zesenzo kunye noxinzelelo olulodwa lweemveliso ze-biotherapeutic (SS-LBP), ukulandela izibonakaliso ezikhokelayo kwi-ulcerative colitis (UC), kunye nosulelo lwe-C. difficile (CDI). Ukongeza kwiiprogram ezimbini zeSigaba soku-1 (i-UC & CDI) kunye nenkqubo yeSigaba se-2 (UC), i-Adiso iphuhlisa inkqubo ye-inflammasome ye-novel kwisigaba sokufumanisa esiqala ukuphononongwa ngokuvutha kokuphefumula, kunye neendawo ezininzi zonyango ezinokubakho kwixesha elizayo.
Inkampani inabasebenzi abangama-25 abathe ngaphambili, phantsi kwesambrela saseMorningside, bavula ngempumelelo ichiza eliTsha loPhando (INDs) kwaye bafake amalungelo awodwa omenzi wechiza amaninzi kunye nokufumana i-US FDA Fast Track Designation, ekugqibeleni ikhokelele ekusekweni kwe-Adiso. I-Adiso iza kusebenza phantsi kobunkokheli beGosa eliLawulayo elisanda kuqeshwa, uScott Megaffin. UMnu Megaffin uneminyaka engama-30 yamava eshishini kunye nerekhodi eliyimpumelelo kwiindima zobunkokeli eziphezulu eBristol-Myers Squibb, Pfizer, Schering-Plough, Adolor, Onconova, naseChurchill. Kutshanje, uMnu. Megaffin usebenze njenge-CEO ye-Adastra Pharmaceuticals, inkampani yophuhliso lwezonyango lwe-oncology, apho akhokele inkampani kwintengiselwano eyimpumelelo ne-Cothera Bioscience ngo-Okthobha ka-2021.
"Iimfuno zonyango ezingafezekiyo zikhoyo kunyango olutsha olujolise kwibhayoloji esisiseko yezifo ezivuthayo ngaphandle kokubangela i-systemic immunosuppression," utshilo uJason Dinges, uMcebisi weMorningside Technology kunye neLungu leBhodi ye-Adiso. “U-Adiso uphuma ngesango ngeenkqubo ezintathu ezithembisayo zonyango kunyango lwe-ulcerative colitis kunye nokuthintela ukuvela kwe-CDI. Sikholelwa ukuba phantsi kobunkokeli bukaScott kunye neqela elinetalente ephezulu yabaphuhlisi beziyobisi, u-Adiso ulungele impumelelo. "
“E-Adiso sijongana nezifo ezosulelayo ngeendlela ezahlukeneyo kunye nendlela enesibindi. Sibona inyani entsha yezigulana, inyusa inkqubela phambili eyaziwayo yonyango losulelo oluthembisa ukubuyisela amajoni omzimba omkhosi, ukuze isifo sosulelo singasebenzi kakhulu kwaye isigulana singakwazi ukukhuseleka, utshilo uScott Megaffin, i-CEO ye-Adiso Therapeutics. . Ndiziva ndinelunda ngokukhokela iqela elikhethekileyo, elikumgangatho wehlabathi, kunye nelizinikeleyo e-Adiso kuphuhliso lwezi nyango zikhethekileyo ziyilelwe ukumisa ngokuchanekileyo ukungasebenzi kakuhle okubangelwa kukudumba.”
U-Mustafa A. Noor, MD, FACP uye wajoyina iqela lobunkokeli be-Adiso. UGqr. Noor uthatha isikhundla seGosa eliPhezulu lezoNyango, ezisa iminyaka engaphezu kwe-20 yobungcali bophuhliso lwamachiza kwiindawo ezininzi zonyango kwiindawo ezininzi zokuqala ukuya kwinqanaba eliphakathi kunye nehlabathi jikelele kuquka i-AMAG Pharmaceuticals, i-Akcea Therapeutics, i-Ipsen, i-Pfizer, i-Glaxo-Smith Kline. , kunye noBristol Myers Squibb.
“Ukudumba kungundoqo kwizifo ezininzi ezinobuzaza kwaye umonakalo owubangelayo uyonakalisa impilo nentlalo-ntle yezigulana. Ukhetho lwangoku lonyango alunelanga ukumisa ukuqhubela phambili kwesifo kunye nokuphucula umgangatho wobomi ngendlela ekhuselekileyo nenenjongo, "kusho uDkt Noor, i-CMO ye-Adiso Therapeutics. “Ezona mpawu zikhethekileyo zepotfoliyo ye-Adiso kunyango lwezifo ezivuthayo zinamandla okuba ngamayeza amatsha kwizigulana. Ukwakhela kwizifundo eziyimpumelelo zangaphambi kweklinikhi kunye nezifundo zokuqala zeklinikhi ukuza kuthi ga ngoku, ndijonge phambili ekukhokeleni amanqanaba alandelayo ophuhliso lwezonyango kwipotifoliyo yethu kunye neqela elinamava labaphuhlisi bezonyango. "
INTO ONOKUYITHATHA KWELI NQAKU:
- We envision a new reality for patients, leveraging known advances of inflammatory therapeutics which promise to recalibrate the immune system of the host, so that the underlying inflammatory disease is neither overactivated nor does the patient becoming immunocompromised,”.
- Building on the successful preclinical and early clinical studies to date, I look forward to leading the next stages of clinical development of our portfolio with an experienced team of clinical developers.
- CDI) and a Phase 2 program (UC), Adiso is developing a novel inflammasome program in discovery phase which is being initially explored in respiratory inflammation, with multiple future potential therapeutic areas to pursue.
